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1 INTRODUCTION 
Intellectual property rights constitute an important aspect of public policies trying to enhance the 
incentives for innovation. Patent systems frequently form the core of such policies, and 
appropriately, they have found considerable attention in the law and economics literature on 
innovation.1 Yet, two important aspects of patent rights still require considerable attention. First, 
patents endow their holders with passive rights. A patent holder may have to defend his patent 
against legal challenges seeking to cast doubt on the validity of the patent right as well as against 
infringement, e.g., via imitation of the patented technology. The efficacy of the legal mechanisms 
by which patents can be defended may have considerable impact on R&D and innovation 
incentives. Even the most comprehensive patent system cannot work well if the rights allocated to 
patent holders cannot be enforced or defended in court, or if the enforcement or defense is too 
costly. While this point is particularly relevant for the case of infringement, the principal problem 
also occurs when a patent is defended against the legal claim that it is invalid. 
Second, some attacks on patents should clearly succeed. The patent system itself is not a flawless 
mechanism. Just as legal decisions in courts may be subject to erroneous decision-making, some 
decisions made by the staff of patent offices may turn out to be flawed. For example, some 
evidence on prior art may be available and relevant for the examination of the patent's extent of 
novelty. But the relevant document may have been overlooked or out of the immediate reach of the 
examiner. The information may surface only after the patent has been granted. Other errors may 
occur in the translation processes at supranational institutions, yielding patent rights that have an 
unintentionally broad scope.2 The examination of patent rights can be interpreted as a design 
process in which the breadth and scope of the patent right is carefully designed such as to achieve 
an optimal tradeoff between R&D incentives and losses of static welfare due to the exclusion of 
competitors. Errors in the examination of patent applications can then have serious welfare 
consequences. The correct design of a patent right should matter particularly for highly valuable 
                                                 
1  A survey of patents as economics indicators is provided by Griliches (1990). For recent theoretical 
contributions to the analysis of patent systems see Scotchmer (1991, 1996) and Merges and Nelson 
(1990). 
2  On December 8, 1999, the European Patent Office (EPO) granted patent EP 0695351. In its English 
translation, claim 49 of this patent refers to “a method of preparing a transgenic animal”. In English 
scientific language, the term animal also includes humans while the European Patent Convention 
explicity rules out patents on humans. Thus, the English-language version of the patent did contain an 
error. But an EPO patent grant – once issued – cannot simply be revoked or amended by the European 
Patent Office itself. Instead, the validity of this patent must be challenged in the opposition process of the 
European Patent Office. This is currently the case for the said patent. For details see the press release 
1/2000 (http://www.european-patent-office.org/news/pressrel/2000_02_22_e.htm as of June 1, 2001) of 
the European Patent Office. Our description follows the interpretation of the European Patent Office. 
Several public interest groups such as Greenpeace have published their own assessments which argue that 
the EPO is acting in the interest of commercial players. 
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patents (i.e., patents that grant the owner a very strong economic advantage). Hence, it should be 
particularly relevant (in a welfare-maximizing sense) to specify valuable patent rights correctly. 
The opposition mechanism at the European Patent Office is of interest with respect to both 
questions. Opposition can be considered an early form of litigation in which opponents may argue 
that a patent grant issued by EPO should be either revoked or amended. The opposition process can 
be initiated by any third party. By its very nature the process allows opponents to threaten the 
position of a patent holder and may therefore undermine R&D incentives. At the same time, since 
it is frequently initiated by competitors of the patent holder, the opponents may be able to generate 
information about the appropriate specification of the patent which has not been available to the 
patent office’s examiner. Thus, it may have the potential of generating information for those 
patents where a correct design of the patent right matters the most, i.e. for valuable patents. 
Studying this mechanism is not just an academic exercise, since opposition is a relatively frequent 
event – on average, 8.2 percent of the patents granted by the EPO are subject to opposition.3 
Despite its obvious importance, the economics of this institution are virtually unknown, and there 
have been no studies analyzing it in detail. To the best of our knowledge, this paper is the first 
study to put forth an econometric study of the determinants of opposition at the European Patent 
Office.4 We therefore see this paper as a counterpart to recent U.S. studies which have focused on 
patent litigation.5 The results of these studies cannot easily be transfered to the European context, 
since legal mechanisms and institutions differ considerably. Thus, there is an obvious motivation 
for undertaking a study the European institutions, and in particular of the opposition procedure. 
An analysis of post-grant opposition is not only relevant in the European context – the institution 
per se is of some interest, since it may offer a relatively efficient solution to a number of problems. 
Uncertainty about the validity and scope of patent rights can have considerable negative 
implications. Firms may delay investments if they expect another firm to enter a market under 
patent protection. But the patent holder himself may also delay the exploitation of a patent if the 
extent of legal protection against imitators is unclear. Moreover, in the case of objectively 
erroneous decisions by a patent office, it is quite obvious that a fast and inexpensive resolution of 
the legal disputes could improve the incentive properties of the patent system. 6 Merges (1999) has 
                                                 
3  This is computed from the number of opposition cases filed against patent grants of applications filed 
between 1978 and 1992. For data sources, see section 4 of the paper. 
4  Van der Drift (1989) is the only earlier study we are aware of in which opposition data are used to 
classify patents according to their importance. The role of opposition as a predictor of patent value is 
emphasized in Harhoff, Scherer and Vopel (1999). Their study shows that patents that survived 
opposition are on average ten times more valuable than comparable patents which were not attacked. 
5  See Lanjouw and Schankerman (2001) for an exploration of the determinants of patent litigation in the 
U.S., and Lanjouw and Lerner (1998) for a survey of the empirical literature. 
6  Obviously, any institution that can correct errors may also be capable of introducing new ones. Moreover, 
the institution itself may introduce uncertainty for the participating actors. It will be very important to 
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recently argued that an inclusion of post-grant opposition may improve the efficiency of the U.S. 
patent system. He explicitly refers to the recent onslaught of patent grants protecting business 
models and software in the U.S. The re-examination procedure in the U.S. patent system does not 
appear to be an attractive early -stage litigation mechanism, and litigation in U.S. courts is costly 
and time-consuming. To correct possible errors made by the patent office relatively soon after the 
patent has been granted, Merges (1999) therefore suggests to introduce a post-grant system similar 
to the one present in Europe and a number of individual European countries, such as Germany.7 
This proposal is currently being pursued in the U.S. House of Representatives where legislation 
HR 1332/1333 is pending under which an opposition system will be introduced into the U.S. patent 
code. While the overall setup of this system is remarkably similar to the one at the EPO, opposition 
would would be limited to business method patents if the legislation were enacted as proposed. 
In this paper, we concentrate on the biotechnology and pharmaceuticals industries, since legal 
disputes appear to arise quite often in these fields (Lanjouw and Schankerman 1999, Lerner 1995). 
We first apply the Priest and Klein (1984) model from the literature on litigation and settlement in 
order to formulate our hypotheses for a world of diverging expectations and idiosyncratic payoffs. 
These imply that the more valuable patents should be particularly prone to attacks. Moreover, a 
host of other models imply that the more asymmetrically the information is distributed between 
patent holder and opponent, the more likely is a case of opposition. We use these predictions to 
select appropriate regressors for our probability models, and we discuss issues of 
operationalization in some detail. We then use a multivariate probit model to test our hypotheses. 
The incidence of opposition is surprisingly high: in our data, 8.6 percent of all biotechnology and 
pharmaceutical patent grants are opposed. Using indicators like citations and patent family size, we 
can show that valuable patents are particularly likely to be attacked. Moreover, opposition occurs 
frequently in areas with considerable technical or market uncertainty. In technical areas where a 
large number of patents exist, opposition is more likely to occur. The rights of patent holders 
appear to “collide” in this case quite frequently, possibly due to intense competition among the 
owners of the patent rights. While limitations of our data do not allow us to look at the interaction 
between holders of opposed patents and their opponents, we find that patents of firms with strong 
patent portfolios appear to be attacked less often than patents of their competitors with smaller 
portfolios. This result may suggest that the incidence of opposition is also determined by the firms’ 
                                                                                                                                                   
study if the opposition mechanism can be employed strategically, e.g., by financially strong firms which 
want to deter entrants from exploiting their patent rights. 
7  Other countries which have incorporated some type of opposition mechanism in their national patent 
code include Australia, China, Japan, South Korea, and New Zealand. Most of these mechanisms are 
post-grant opposition proceedings. Some pre-grant opposition systems appear to have been abused 
strategically by opponents seeking to delay the grant. Most post-grant opposition systems allow third 
parties to attack the validity within a short time period after the grant. Typically, there is a presumption 
that the patent is valid during the opposition proceeding until it is either declared invalid or amended in 
some form. 
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capability of deterring hostile acts in some unobserved way. The advantage of the firms with large 
portfolios is getting weaker, however, as a technical field gets more crowded. Ceteris paribus, 
patents held by independent inventors are not more likely than corporate-owned patents to be 
attacked. This is an important result, since it suggests that there is no first-hand evidence that 
independent inventors will suffer from strategically filed opposition. However, the result does not 
rule out completely that strategic behavior exists in opposition filings. 8 
We also discuss the implications of these results and possible extensions of our research in the 
paper. Most significantly, we confirm that patents with above-average values are more likely to be 
attacked. This conclusion is an indirect one, since we do not have access to direct measures of 
patent value. However, the indicators used in this study have repeatedly been shown to be reliable 
proxies for a patent’s value. Based on our results we suggest that the opposition system in Europe 
may be quite efficient in resolving legal uncertainty, in particular for economically relevant 
patents. At this point, this is a mere supposition, since the opposition system in Europe is a slow-
moving process in which cases get on average decided about four years after the opposition has 
been filed. 
The remainder of the paper is structured in five sections. We first discuss the institutional elements 
of the European Patent Office and its associated procedures. The institutional information provided 
in section 2 forms the background of our theoretical discussion in the subsequent section 3 in 
which we develop our hypotheses. Section 4 discusses data sources and the computation of key 
variables. In section 5, we first consider a number of descriptive statistics before setting up and 
estimating multivariate probit equations for the incidence of opposition in the sample studied here. 
In the subsequent discussion, we compare our theoretical expectations and the probit results. 
Section 6 concludes and discusses implications and extensions of this research. 
 
2 Patent Systems in Europe 
National legal systems in Europe display considerable heterogeneity which is a reflection of the 
diverse legal traditions. However, in the area of legal frameworks for patents, harmonization of 
legal institutions has had a long tradition. The advantages of a common European patent law were 
already acknowledged during the last century. Since then there has been a continuous effort to 
align the different forms of national patent legislation in Europe. Such processes of legal alignment 
                                                 
8  There may be strategic effects at work which we cannot detect with our data. For example, large 
opponents may have an incentive to extend and delay opposition proceedings against independent 
inventors in order to drive the costs of the proceedings up. See section 6 for comments on the possibility 
of such effects. 
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in Europe are translated into action on a contractual basis. Thus, the national jurisdictions of the 
sovereign member states are not abolished and continue to exist in parallel to the new 
supranational contracts.  
It is for the same reason that Europe has reached a remarkable consensus on the patent filing and 
granting process reflected in a widespread use of supranational filing and granting mechanisms. At 
the same time, with regard to patent litigation before courts, the legal heterogeneity of Europe is 
still prevailing. The opposition procedure at the European Patent Office, however, can be regarded 
as a centralized "first-instance challenge suit" for EPO-granted patents and can thus be compared 
to patent litigation in U.S. civil courts. In the following we try to set out important details of 
European patent legislation in a very condensed form. 
2.1 Historical Aspects 
Three milestones in European patent legislation can be identified in retrospective: the passing of 
the Paris Convention for the Protection of Industrial Property in 1883, the rectification of the 
Patent Convention of Strasburg in 1963, and the conclusion of the European Patent Convention in 
Munich in 1973. Before 1883, supranational arrangements did not exist in Europe in the field of 
intellectual property rights. Neither the premises nor the consequences of the different jurisdictions 
were recognized in other countries. It was due to growing international industrialization that a need 
for international validity of intellectual property rights was articulated at the end of the last century. 
As a consequence, in 1883 the leading European countries of the time agreed on treating foreign 
patent holders like domestic patent owners; besides, patent priorities could from now on be 
claimed internationally. After this first step no further need for legal harmonization was felt until 
the end of the second World War. The efforts of the European Economic Community (EEC) 
towards trade liberalisation and the establishment of a common market in Europe led to the Patent 
Convention of Strasburg in 1963. The significance of this treaty lies in the alignment of terms of 
material patent law, such as novelty or inventive step.9 This alignment of material right terms in the 
different national legislation was a necessary step towards the conclusion of the European Patent 
Convention (EPC) in 1973. The EPC is nowadays the most important source of common European 
patent law. As a special agreement referring to the Paris Convention for the Protection of 
Industrial Property in 1883 it regulates the filing and granting process of common European 
patents. It covers both, formal and material aspects of patent law. As of April 1998, nineteen 
European states had confirmed the treaty. By doing so they acknowledge that centrally examined 
and granted European patents are given the same validity as nationally granted patents. They also 
agree that granted European patents can be centrally attacked via opposition, i.e., in a procedure 
                                                 
9  For a definition of "novelty" and "inventive step" see section 2.3. 
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comparable to a "first-instance challenge suit". Traditional national litigation on infringement or 
the validity of the patent before national courts remains untouched, but loses importance.10 
2.2 European Patents 
The conclusion of the European Patent Convention in 1973 prepared the ground for the creation of 
a central European Patent Office which has its headquarter in Munich. Between 1978 and 1999, the 
European Patent Office has received 1.267,681 patent applications and has granted 479,133 
patents.11 It has therefore become one of the most important patent offices in the world. Figure 1 
displays the number of EPO applications and patent grants from 1978 to 1999. 
Patent protection for European member states can be obtained by filing several national 
applications or one EPO patent application designating the states for which patent protection is 
requested. Considering the fees charged by the various patent offices in Europe, a European patent 
application costs approximately €29.800 and thus about three times as much as a typical national 
application.12 Thus, if patent protection is sought for more than three designated states, the 
application for a European patent becomes cheaper than independent applications in several 
jurisdictions. This cost advantage has made the European filing path particularly attractive for 
applicants that are selling goods and services in international markets. Due to the increasing 
application and grant numbers, the European Patent Office has now gained a level of economic 
importance similar to that of the United States Patent and Trademark Office (USPTO). Moreover, 
the opposition procedure before the European Patent Office has become an important instrument 
for first-instance challenges to the validity of patents granted by the EPO. 
2.3 The Application and Examination Process 
European patents are granted for inventions which are novel, mark an inventive step, are 
commercially applicable, and are not excluded from patentability for other reasons. After the filing 
of the application, a search report is provided by the EPO and made available to the applicant. The 
search report is generated by EPO staff in the The Hague office and then transferred to the 
examining staff in the Munich office. It describes state of the art regarded as relevant according to 
                                                 
10  In addition to the mentioned supranational contracts, two other treaties have assumed major significance 
for Europe, i.e. the Patent Cooperation Treaty (PCT) and the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS). However, since these two treaties are global treaties rather that 
inter-European agreements, they will not be discussed in detail in this paper. 
11  See the European Patent Office Annual Report 1999, Table 7.6. The application and grant figures include 
so-called Euro-PCT applications. 
12  As in other patent systems, the official patent office fees are a relatively small part of the costs (in this 
case €4,300). Professional representation before the EPO amounts to €5,500 on average, while translation 
into the languages of eight contracting states requires €11,500. Renewal fees for a patent maintained for 
ten years amount to roughly €8,500. 
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EPO guidelines for the patentability of the invention. In particular, the examination report lists and 
classifies references to earlier patents or to documents in the non-patent literature according to the 
guidelines for substantive examination issued by the World Intellectual Property Organisation 
(WIPO). So-called A references simply describe the state of the art without posing a threat to the 
novelty claims in the application. Other classes of references (Y and X) are potentially harmful to 
the novelty claim and may therefore signal to the applicant (and to outsiders once the research 
report is published) that the patent application is weak. Category X is applicable when a referenced 
document is such that even when taken alone, a claimed invention could possibly not be considered 
novel or could not be considered to involve an inventive step. Category Y is applicable when a 
referenced document is such that a claimed invention could possibly not be considered to involve 
an inventive step when the document is combined with one or more other documents of the same 
category, such combination being obvious to a person skilled in the art. Documents are classified 
by the EPO staff members in Den Hague who prepare the search report. The classifications 
therefore have pre-examinatory status, i.e., they are re-evaluated during the material examination in 
Munich. As we will argue later, a patent grant emerging from an application with a large number 
of X references may attract the attention of possible opponents. 
Within six months after the announcement of the publication of the search report in the EP 
Bulletin, the applicant can request the examination of his application which is a compulsory 
prerequisite for the patent grant. If examination is not requested, the patent application is deemed 
to be withdrawn. Eighteen months after the priority date the patent application will be published. 
At this point, the application will normally still be under examination; thus, the patent owner will 
already reveal some information prior to the grant of the patent. Moreover, the content of the 
application is revealed even if no patent is ever issued. If engaged with the examination, the EPO 
will present an examination report; either the EPO will inform the applicant that the patent will be 
granted in the way it was applied for, or the EPO will propose changes after which the patent could 
be granted if the invention was patentable at all. In the latter case it is up to the applicant to decide 
whether to accept the alterations proposed by the EPO, or to come up with a different proposal for 
alteration. Once the applicant and EPO have reached a consensus on the version of the application 
to be granted, the patent is centrally granted for all the designated states and then translated into the 
respective languages. If no such agreement is reached and if the EPO declines to grant a patent, the 
applicant may turn to the appeals proceeding in which the reasons for the refusal to grant a patent 
right are reconsidered.13 After the grant, the European patent becomes a “bundle” of national patent 
rights. On average, the granting process for a European patent takes about 4.2 years from the date 
of filing the application. 
                                                 
13  This form of appeal has to be distinguished from appeals seeking to reverse the decisions rendered by the 
opposition division of the EPO. 
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2.4 The Opposition Procedure 
Once the European patent is granted, its national successors are treated like “normal” national 
patents that can be attacked by third parties through legal means allowed for by the respective 
national legislation. Outcomes of such national litigation cases are always restricted to the national 
level, e.g., the patent may be invalidated in Spain, but this does not affect its validity in Italy. Up to 
nine months after the granting date, however, third parties can attack the European patent centrally 
at the European Patent Office by filing their opposition aga inst the granting decision. Comparable 
to the granting decision, the outcome of the opposition procedure is again binding for all 
designated states. The opposition procedure is thus the only central “challenge suit” for European 
patents. After the expiration of nine months subsequent to the grant, a competitor will have to 
attack the succeeding national patents of the European patent in each jurisdiction separately. 
Opposition to a European patent is again filed with the EPO. The opponent has to substantiate his 
opposition by presenting evidence that the prerequisites for patentability were not fulfilled, e.g., he 
has to show that the invention lacked novelty, and/or an inventive step, or that the disclosure was 
poor or insufficient. The opposition is formally admitted by the EPO where an opposition division 
decides on the case. At the end of the opposition procedure the chamber may uphold the patent 
without amendments, or it may amend14 or even revoke15 the patent. Patents are revoked in about 
one third of all cases.16 The decision affects all of the “designated states,” i.e., the states for which 
the patent applicant sought to obtain a patent  
A further interesting aspect of the opposition procedure that distinguishes it from a “real” litigation 
before civil courts concerns the possibility of settlement between the litigating parties. Once an 
opposition is filed, the EPO may continue to decide on the case even if the opponent does no 
longer actively pursue opposition. Thus, opponent and patent holder may not be free to settle their 
case outside of the EPO opposition process once the opposition is filed.17  
Both the patent holder(s) and the opponent(s) may file an appeal against the outcome of opposition 
procedures. The appeal has to be filed within two months after the receipt of the decision of the 
opposition division, and it has to be substantiated within an additional two months. The Board of 
Appeal is the final instance at the EPO to decide on the validity of the contested European patent. 
                                                 
14  An amendment normally results in a reduction of the “breadth” of the patent by altering the claims which 
define the area for which exclusive rights are sought. See Straus (1996) for a detailed discussion of the 
legal status of the patent rights during this process. 
15 On average, the opposition procedure takes around 2.2 years if the patent is revoked and about 4 years if 
the patent is amended. 
16  See EPO (1999), p. 17 and Merges (1999), pp. 612-614. For the sample used here, we did not have access 
to data on the frequency and extent of amendments, or the frequency of rejected oppositions. 
17  EPO may, but will not necessarily pursue the opposition procedure after the opponent’s withdrawal from 
his attack. 
  9 
The official fee for filing an opposition is €613; for filing an appeal against the outcome of 
opposition, the fee is €1022. But the total costs to an opponent or the patent holder are much 
higher. Estimates by patent attorneys range between €15,000 and €25,000 for an opposition case 
(for each party). Approximately the same amount would be due for an appeal against the outcome 
of the opposition proceedings. 
Figure 2 displays the rate of opposition for the time period from 1980 to 1998.18 We plot here the 
number of opposed patent grants divided by the total number of patents granted in a particular 
year. Leaving aside the early period after the EPO commenced operations, the rate of opposition 
has intially been on the order of 8 percent. It has been declining to about 6.5 percent over time, but 
it is still extremely high in comparison to the likelihood of patent litigation in the U.S.19 The 
discrepancies between the U.S. and EPO figures may mainly be driven by cost differences.  
2.5 National Litigation 
In cases of unsuccessful opposition and appeal against commercially valuable patents, third parties 
may try to attack the national successors of the European patent in the designated states. As of 
today, this option is not touched by the harmonisation of the European patent laws. However, 
national authorities can refer to former trials, thus, the probability of winning a national trial after 
having lost at the European level may be reduced. The differences across national jurisdictions are 
still enormous. Economies of scale are therefore difficult to achieve, thus making it quite expensive 
to attack the national successor patents in all of the designated states. The costs for litigation in any 
one of the national courts have been estimated to be between €50.000 and €500.000, depending on 
the complexity of the case. This cost structure makes an attack at the European level via the 
opposition procedure particularly attractive for a potential competitor of the patent holder. The 
litigation rate (computed as the number of cases for which a suit is  filed divided by the number of 
patents) in most European countries is roughly one percent, slightly lower than in the United States 
(Stauder 1989, 1996). But there is not sufficient evidence at this point to conclude that the 
existence of the opposition mechanism leads to a reduction in litigation. 
                                                 
18 Since opposition must be filed within nine months after a patent is granted, the application cohorts from 
1978 to 1996 were attacked by opposition cases dated between roughly 1980 and 1998. The lag 
corresponds to the examination period between application and grant. 
19 Lanjouw and Schankerman (2001) estimate the incidence of validity challenges to be at 1.05 percent of 
all patent grants in the drugs and health field (which in their case includes cosmetics). See Lanjouw and 
Schankerman (2001, Table 1). The authors of this study point out that many of the US challenge suits 
against patents arise as a consequence of infringement suits. A frequently observed move by the 
defendant is to assert that the infringed patent had no validity in the first place. 
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3 Theoretical Aspects - The Selection of Opposition Cases 
3.1 A Simple Theoretical Model 
In order to derive our hypotheses in a systematic manner, we briefly introduce a simple formal 
model of opposition which is based on the classical study by Priest and Klein (1984).20 To simplify 
matters, we consider a world in which parties make imprecise assessments of case quality and 
decision standards, but where information is distributed symmetrically.21 The opponent and the 
patent-holder may have diverging subjective assessments of the outcome of the case, but the value 
of the patent (i.e., the profits in the duopoly or monopoly case) are given. To qualify for 
opposition, any case must satisfy the condition that the expected value for the opponent must 
dominate the expected cost of opposition. In other words, we rule out that the opponent “bluffs” 
and threatens to oppose in circumstances under which the true expected benefit from opposition is 
lower than the cost.22 If the suit is feasible, then the parties may still settle prior to the expiration of 
the opposition period, i.e. within nine months after the patent has been granted. We formulate these 
two conditions in the context of a simple model and then discuss some of the comparative statics in 
a stylized manner. 
In the case of opposition proceedings, it is important to recall one distinct institutional feature. 
Once filed, the European Patent Office can pursue an opposition case even if the parties involved 
have achieved some kind of understanding. Suppose that the case has been filed, but the opponent 
has withdrawn after obtaining a license from the patent holder. Such a settlement would be 
attractive, since both firms will now enjoy patent protection (even if the patent has been assigned 
erroneously or if it grants too much scope to the owner and licensees). The European Patent Office 
may nonetheless pursue the case and subsequently revoke the patent. We would therefore assume 
that settlement negotiations tend to take place mostly prior to the filing of the opposition (if at all). 
Thus the following considerations are based on the assumption that once an opposition is filed, it is 
also tried. Settlement may take place, but it would occur prior to filing the case.23 Thus unlike the 
case of litigation, where we observe the filing of suits even if they are settled before trial, we do 
not observe opposition cases that “settle.”  
                                                 
20  Lanjouw and Lerner (1998) uses the Priest and Klein model to interpret conditions under which 
infringement cases will be brought to trial. 
21  In Waldfogel’s terminology, this is the case of divergent expectations (DE) which he carefully 
distinguishes from the case of asymmetric information (AI). Since we cannot distinguish among the 
different theories in our data, we do not present the arguments in detail. See Waldfogel (2000) for an 
empirical test the results of which favor the DE hypothesis. 
22  Frivolous suits are possible under asymmetric information, which we rule out (Bebchuck 1984). 
23  Our interviews with patent attorneys suggest that this is indeed the case - estimates of the settlement 
frequency range suggest that between 10 and 25 percent of disputes are not filed, but settled between the 
parties. 
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We distinguish two cases. Our first case is one in which successful opposition to a patent grant 
transforms a monopoly to a duopoly. Suppose that a patent has been granted to one firm and the 
patent would allow the firm to earn monopoly rents MP . Another firm considers the benefits and 
costs from filing an opposition and letting it go to trial versus settlement of the dispute. The trial 
can only have two outcomes – the rejection of the opposition or the revocation of the patent right. 
Should the opponent prevail in having the patent revoked, both firms will be able to earn duopoly 
profits DP  in the market.24 If the opposition is rejected, the attacker will receive zero profits. Note 
first that the case will only qualify for opposition if  
 O
D
O cp -P  > 0 (1) 
where Op  is the likelihood of successful opposition as perceived by the opponent, and the 
opponent’s total cost of opposition proceedings is given by Oc  which we treat as exogenously 
given for now. Cases that qualify for opposition may either be settled or tried. For our discussion 
of a pre-trial settlement solution, the threat point of the opponent is given by 
 O
D
O cp -P  . (2) 
The threat point for the patent holder is given by its expected value from trial 
 ( ) PDPMP cpp -P+P-1  (3) 
where Pp is the likelihood of successful opposition as subjectively perceived by the patent holder. 
The cost of opposition proceedings (including attorneys’ and patent office fees) is given by Pc .  
The differences in the subjective probabilities simply reflect uncertainty – both parties may assess 
the quality of their case and the decision standard with some error, but no party has any privileged 
information. The trial value of the game is given by the sum of the threat points. The cooperative 
value of the game is the industry profit in case of settlement net of total settlement costs S, i.e., 
SS -P . We treat the profit level in the case of cooperation separately here, since it may exceed the 
industry profits of a duopoly if some collusive elements are present in the licensing or side-
payment setup chosen by the firms. Hence, we assume that DSM P³P³P 2 . Settlement will not 
occur (i.e., opposition will occur) if the trial value exceeds the cooperative value of the game. This 
comparison yields the inequality 
 ( ) ( ) ( ) ( ) ( )DSOPDPODMP ccSppp P-P³--+P-+P-P- 221  (4) 
The first term captures how attractive the monopoly position is as compared to the duopoly case 
from the patent-holder’s perspective. The higher the wedge between monopoly and industry 
duopoly profits, the less likely the patent holder is to settle, in particular if he perceives the 
                                                 
24 If entry is free, more firms may enter so that profits are driven to zero. Note that in this case the opponent 
may not wish to oppose the patent, since the opposing firm creates a public good for every other firm in 
the industry, but bears the full cost of trial. In this case the threat point is negative. 
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likelihood of successful opposition to be low. Ceteris paribus, we would expect this difference to 
grow with the level of monopoly or duopoly profits. The second term captures the effects of 
diverging expectations of case quality and decision standards. If the opponent is optimistic (i.e., if 
his subjective probability of winning is higher than the patent holder’s assessment), then litigation 
will again become more likely, especially if the level of duopoly profits is high. The third term 
captures the cost disadvantage (or advantage) of the settlement solution – high trial costs will make 
settlement more likely, high settlement costs will drive the parties to a trial solution, ceteris 
paribus. One would usually assume that settlement is less costly than a trial. In the case of 
opposition against patent grants, this conclusion is not necessarily warranted. First, the costs of 
conducting the trial are born by the European Patent Office. The two parties involved have to take 
into account a fee for filing opposition and attorney costs. Since the filing fee is minor25 and since 
settlement negotiations would also be conducted by attorneys, settlement may actually be more 
expensive to the parties than the trial. Finally, the term on the right-hand side of the inequality 
captures the effect of a cooperative solution. The higher the settlement profit is in comparison to 
the duopoly solution, the more likely settlement will be. This term will be zero if cartel authorities 
do not allow firms to enter arrangements that leave them more than the duopoly profits. 
Now we consider another case in which successful opposition actually functions to maintain a 
monopoly. Suppose that a firm has received a patent that allows it to enter an industry dominated 
by an incumbent. The entrant’s patent may, for example, protect a technology that neutralizes the 
former technological lead of the incumbent. In this case the incumbent may oppose the patent 
right, since it threatens the existing monopoly. The threat point of the ex ante monopolist (the 
opponent) is given by 
 ( ) OMODO cpp -P+P-1  (5) 
while the entrant views 
 ( ) PDP cp -P-1  (6) 
as her threat point. The condition for an opposition case to be filed and tried is then given by  
 ( ) ( ) ( ) ( )DSOPDPODMO ccSppp P-P³--+P-+P-P 22 . (7) 
As a comparison of (4) and (7) show, ex ante asymmetries in the market positions may affect 
incentives to file an opposition case. Hence, a structural approach to estimation would also 
necessitate a careful operationalization of the market conditions. For our reduced form estimation, 
however, the conclusions for the two cases are similar. As the stakes increase and as the cost 
advantage of settlement decreases, opposition is more likely to occur. 
                                                 
25  See section 2.4 for details. 
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We demonstrate these points graphically for the first case in which the opponent can gain a 
duopoly position if the opposition case is successful. In Figure 3, we consider a profit-probability 
space und characterize parameter regions in which opposition would occur. To simplify matters, let 
us assume that diverging expectations are not present. Hence, in equation (4) the second term 
would vanish. We also assume that the settlement solution duplicates the duopoly solution, i.e., 
antitrust authorities can prevent firms from engaging in collusive licensing agreements. Hence, the 
right-hand side term in equation (4) is zero. Furthermore, let the monopoly profit MP be equivalent 
to ( ) D?a2 +  where a>0 measures the attractiveness of the monopoly position as compared to the 
industry profit in a duopoly. Equation (4) implies that for opposition to occur we need 
 ( ) ( )OPD ccSp ---³P- a1  (8) 
Moreover, recall that for opposition to be feasible in a world without bluffs, we have to have 
 O
D cp -P  > 0. (9) 
In Figure 3, we plot parameter combinations of p and DP  that satisfy these conditions. As can be 
seen from this figure, higher settlement costs SS > make opposition more likely, since the locus 
of equation (8) shifts downwards. Similarly, higher costs of opposition (to the opponent) 
OO cc > make opposition less likely to occur, and an increase in the level of profitability (as 
measured by the level of duopoly profit DP ) will tend to enlarge the range of p-values for which 
opposition occurs. Moreover, equation (8) demonstrates that larger values of a will also shift the 
locus of the settlement curve downwards – the likelihood of opposition (non-settlement) increases 
as the monopoly position becomes more attractive. 
These simple considerations neglect the possibility of asymmetric information. In the model 
developed by Bebchuk (1984), the defendant knows the probability of winning while the plaintiff 
only knows the distribution of that probability. The less well-informed plaintiff makes a take-it or 
leave-it settlement offer which in some cases turn out to be unacceptable to the better-informed 
defendant. These offers will therefore be rejected and a trial ensues. Thus, the likelihood of trial 
versus settlement should increase in the extent of informational asymmetries. Similar conclusions 
emerge from other models with asymmetric information between plaintiff and defendant. 26 We do 
not specify these models in detail, but simply take from them the prediction that as information is 
more asymmetrically distributed, the likelihood of an opposition case increases. 
                                                 
26  See, for example, Png (1983). Waldfogel (1998) provides an empirical test of the diverging predictions of 
AI (asymmetric information) and DE (diverging expectations) models. 
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3.2 Hypotheses 
While there is no single model that captures all possible situations in which opposition cases may 
occur, some conclusions can be drawn from the above and the literature. In particular, we would 
predict that the likelihood of observing opposition increases as 
1. expectations increasingly diverge; 
2. information is distributed more asymmetrically; 
3. the stakes increase, i.e., as the level of profits rises; 
4. the costs of trial (opposition proceedings) decrease in comparison to the costs of 
settlement. 
We do not offer a structural test of these predictions here, since that would require considerably 
more detailed data than were available for this paper. However, a reduced-form test of some of hte 
predictions is feasible. To perform such a test, we first need to identify variables that can serve as 
proxies for the variables implicit in the theoretical models.  
Predictions (1) and (2) suggest that rates of opposition will be particularly high for technical fields 
in which asymmetric information and diverging expectations are pronounced. Increasing 
uncertainty would therefore be associated with higher rates of opposition against patent grants. 
This is likely to be the case for relatively new technical areas, such as special areas of 
biotechnology in which applicants seek patent protection for new microorganisms, enzymes and 
recombinant DNA processes. We use four-digit IPC classifications to test this hypothesis. The 
reference group for our tests are patents whose main IPC classification is C12M. We expect that 
there is comparatively little uncertainty in this field, since it involves the patenting of machinery 
and process equipment. The working principles of the equipment are well-known. Other IPC fields 
taken into account are C12N (microorganisms or enzymes), C12P (fermentation or enzyme-using 
processes), and classical pharmaceuticals (A61K, without cosmetics) for which we expect higher 
opposition rates than for the reference group, ceteris paribus. 
Other features of the EPO research and examination system allow us to capture situations of 
asymmetrically distributed information. Recall that the process of communication between patent 
applicant and patent examiner is a kind of negotiation. By and large, we would expect the patent-
holder to be well-informed about this process while the potential opponent has no direct knowledge 
of the information exchanged. This is particularly relevant when novelty and inventive step of the 
patented invention are assessed in comparison to the state of the art. As described in section 2.3 of 
the paper, the patent examiner receives a research report from EPO office staff at the The Hague 
office in which the research branch of the EPO has collected prior art and has labelled these 
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references – X-labeled references indicate prior art that is a potential threat to the novelty claims of 
the patent. The research report is published at some point by the EPO – we therefore assume that 
similar information will be available to the potential opponent, but that the result of the 
communication process will only be known to the patent applicant and the examiner. Thus, to the 
extent that the discussion resolves disputes between examiner and patent applicant, the opponent 
will find itself disadvantaged with respect to the information she has about the examination and 
granting process. While this is generally the case, we consider patents with a large number of X-
labelled references to be particularly exposed to informational asymmetries.27 
Prediction (3) states that the likelihood of opposition will increase with the value of the patents in 
dispute. We do not have estimates of the monetary value of the patents considered here. But from 
earlier studies we know that there is a strong relationship between patent value and the number of 
citations that a patent receives from subsequent patents. 28 Furthermore, an additional indicator of 
patent value is the size of the patent family, i.e., the number of jurisdictions in which patent 
protection has been granted for the invention. We use the number of designated states for which 
the applicant obtains patent protection once the European patent becomes a bundle of national 
patent rights as an additional proxy for patent value. The number of references to prior patents and 
to the non-patent literature29 have also been found to be positively related to patent value (see 
Harhoff, Scherer and Vopel 1999). These measures have also been constructed for the present 
dataset, but their sign is not unambiguous. For example, references to prior art described in the 
scientific literature may be correlated positively with patent value, but may also strenghten the 
patent against legal attacks such as opposition. In our empirical estimates both effects may be 
present, and on theoretical grounds alone it is not clear which effect will dominate.  
Prediction (4) cannot be tested using our data, since we do not observe the costs of opposition or 
settlement. Nor do we have proxy variables at hand which we can utilize to this purpose. But we 
hypothesize that patent holders with relatively large portfolios will be able to offer settlement 
offers to attackers more easily than other patent holders, e.g., via cross-licensing contracts. The 
value of such agreements should be particularly high in technical fields that are not “densely 
populated” by patents. One can argue alternatively that in industries with substantial licensing, an 
attack on a patent holder with a large portfolio may trigger a non-cooperative response. Large 
patent portfolios may therefore allow the patent holder to retaliate in some fashion against the 
attacker. We would therefore expect a negative effect of patent portfolio size on the incidence of 
opposition. Again, if there are a large number of patents in a technical field in any case, then 
                                                 
27  An alternative interpretation of this variable is that it does indeed indicate patents for which opposition 
will be more successful. Note that in equation (4) the likelihood of observing opposition is increasing the 
success probability, while the reverse holds for equations (7). We cannot measure the correlation between 
the incidence of X-labeled references and outcomes, but intend to do so in the future. 
28 See, e.g., Harhoff, Narin, Scherer and Vopel (1998) and Trajtenberg (1990). 
29  See Meyer (1999) for a survey. 
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bilateral implicit collusion may not be valuable. The effect of a large portfolio is therefore likely to 
diminish as the total number of patents in a field increases. 
Finally, we include a large number of control variables in our probability model. These do not have 
a clear interpretation, but are likely to control for additional sources of variation. First, we 
introduce dummy variables for the most important owner nations. Differences associated with the 
nationality of the owner may be correlated with variations in the average quality of patent 
applications filed with the EPO. To give a simple example: a Japanese firm which has already 
received several patents for its domestic market will not necessarily patent all of its domestically 
protected inventions in Europe, since the additional costs will induce a selection of particularly 
valuable patents.30 Hence, we expect that the quality (and value) of patents owned by European 
patent owners will on average be lower than the quality of Japanese and US patents filed in 
Europe. 
4 Data Issues 
4.1 Data Sources 
We use three different data sources for our study. The ELPAC data base contains information on 
European patents and Patent Applications filed between 1978 and 1996. The data include the 
names of the inventors, applicants and opponents, designated states, process dates, international 
patent classifications and decisions of granting and opposition procedures. Our version of ELPAC 
contains 813,979 observations. We also use information from the ESPACE databank to add 
observations where ELPAC is not complete. The ESPACE databank basically contains the same 
information as ELPAC; however, ESPACE covers the filing and granting process more completely 
than ELPAC whereas ELPAC is more complete with respect to the opposition procedure. Finally 
we draw information on citations from the REFI database. REFI contains data on patent citations 
for 712,315 European patent applications as well as references to the non-patent literature for 
424,962 European documents. 
From these databases, we select pharmaceuticals and biotechnology patents on the basis of the 
main IPC classification. We can identify 13,389 granted European patents in the biotechnology and 
pharmaceutical fields between 1979 and 1996. Of these, 1,158 patent grants (8.6 percent) were 
opposed. 
                                                 
30  See Putnam (1990) for an analysis of foreign filings. 
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4.2 Variables 
In the following sections, we briefly describe the variables computed from our three data sources. 
Opposition. We create a binary variable to distinguish between patents that were opposed from 
those that were not opposed. This variable reflects the endogenous outcome we want to model.  
Backward citations. The search report of the EPO yields information on the state of the art 
relevant for the patentability of the application. State of the art is mostly described by patent or 
non-patent literature. Relevant references are cited (backwards) by the examiners during the 
examination of the patent application. Furthermore, the cited references are pre-classified by the 
EPO office in The Hague which composes the search report prior to examination. The citations are 
pre-classified into different categories as we described in section 2.2.  
However, they serve us as indicators of the extent of asymmetric information between patent 
holder and examiner. In particular, a high share of X documents should go along with significant 
informational advantages on the side of the patent holder. 
For our analysis we construct several variables referring to backward citations. At first, we count 
the overall number of backward citations to relevant patent literature. We also include the share of 
A and the share of X documents in the analysis. We expect that as the share of X documents 
increases, the patent will face a higher likelihood of opposition, ceteris paribus. Conversely, as the 
share of A documents increases, the reverse effect should become apparent. 
References to the non-patent literature. Patents may be based in part or fully on new scientific 
knowledge.31 Since published research results can be used to document the state of the art against 
which the application has to be evaluated, patent examiners will then search for relevant references 
in the scientific literature. As in the case of references to the patent literature, a relatively high 
number of references to the scientific literature may therefore indicate patents of relatively high 
value. Following our main hypothesis, these should be particularly likely to encounter opposition. 
The fact that not all non-patent references refer to scientific sources is well-known. Thus, the 
number of non-patent references is not a direct measure of the strength of a patent's science 
linkage. This problem has been studied in some detail by Schmoch (1993). A survey of the 
literature on this topic is contained in Meyer (1999). However, the number of non-patent references 
is considerably easier to compute than the number of explicit links to the scientific literature. 
Moreover, we also expect that "science-based" patents contain a relatively high number of non-
                                                 
31  The growing importance of the linkage between private patenting activities and scientific knowledge has 
been documented by Narin, Hamilton, and Olivastro (1997). 
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patent references. This is actually borne out by the data (see below). Thus, we maintain the easily 
available indicator which simply counts the references to the non-patent literature. 
Forward citations. If a patent receives citations from other future patents, this is an indication that 
it has contributed to the state of the art. Earlier studies have shown that forward citations are 
positively correlated with the monetary value of the patent (Harhoff, Scherer and Vopel 1999; 
Lanjouw and Schankerman 1999; Trajtenberg 1990). In our paper, forward citations are computed 
within the EPO system only, i.e.m we only identify how many future citations a patent received 
from subsequent European patents. We count the number of references to the patent under 
consideration in patents filed within four years of the filing date of the original patent. 
Number of designated states. Putnam (1991) and other authors have argued that information on 
family size (the number of jurisdictions in which patent protection is sought) may be particularly 
well suited as an indicator of the value of patent rights. Studies by Putnam (1996) and Lanjouw et 
al. (1998) have shown that the size of a patent family and the survival span of patents are highly 
correlated. While we do not observe the global size of the patent family in our data, we can 
construct variables for the designation of the patent in the different member states of the European 
patent Convention. In essence, this reflects the European family size. Given the fee schedule of the 
EPO, it is clear that firms seeking to designate the patent right for a large number of EPC member 
countries face a considerable increase in total patenting expenses. However, there are some 
economies of scale in that some types of fees (e.g., for translation) are fixed. In our multivariate 
analysis, we therefore use the logarithmic transformation of the number of designated states to 
reflect the declining marginal cost of patenting in another EPC country. 
Ownership. An invention can only be made by individuals. The applicant (and later on patent-
holder) may be either an individual, a firm or a group of individuals and firms. We construct a 
variable for the type of ownership (corporate or individual) for each patent by comparing the 
inventor’s and the applicant’s name. The patent is assigned individual ownership if the inventor’s 
name and the applicant’s name are the same. We also create binary variables for owners from the 
U.S., Germany, Japan, France, Great Britain, Switzerland and all remaining countries. 
International patent classification (IPC) assignments. During the EPO research and 
examination process, patents are assigned to 9-digit categories of the IPC system. Patented 
inventions may belong to diverse technological fields, i.e. they may be assigned different IPC 
codes. The broader the relevance of the patent, the more potential opponents it may therefore have. 
The number of different IPC classifications may therefore be positively correlated with the 
likelihood of opposition. This argument is related to Lerner (1994) who suggests that broader 
patents are more valuable ones. An opposing argument would suggest that the likelihood of 
opposition should decrease with an increasing number of different IPC codes, since the invention is 
more general and therefore has less immediate relevance for market outcomes. 
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Previous patents - cumulative EPO patent grants by firm. We construct a further variable that 
counts the number of previous EPO patent grants the applicant has already received. It is plausible 
to assume that the greater the number of patents he holds, the higher the market share will be. 
Moreover, a larger patent portfolio should reduce the impact of a successfully opposed patent, both 
on the applicant's and the opponent's profits. We therefore expect that the likelihood of opposition 
decreases as the number of previous patents increases. 
Crowdedness - cumulative EPO patent grants within technical field. The more attractive a 
technical field, the higher should be the cumulative number of patents. This form of "crowding" is 
likely to raise the likelihood of opposition. Our measure for "crowdedness" is the cumulative 
number of patents within a four-digit IPC classification. 
 
5 Empirical Specification and Estimation Results 
5.1 Descriptive Statistics 
Our empirical analysis is based on data covering all European patents in the biotechnology and 
pharmaceuticals industry with application years from 1978 to 1996. The data include information 
on the filing date, the date of opposition, the number of designated states, the IPC codes assigned, 
the nationality of the patent owner and the type of ownership; furthermore they comprise forward 
and backward citations and references to the non patent literature for each European patent. The 
complete data set contains 13,389 European patents and 1,158 opposition cases (8.64 %). 
Summary statistics for these patents are given in Table 1. Forward citations range from 0 to 36 
citations per patent at an average of about one citation per patent; backward citations range from 0 
to 29 citations at an average of about two citations per patent. The average share of X documents is 
below 10%, the share of A documents around 20% of the cited documents. On average, the 
applicant designates 10 EPC member states when filing his application. 
Tables 2 to 5 display the relationships between the incidence of opposition and four of the 
exogenous variables, i.e., forward citations, backward citations, references to the non-patent 
literature, and the number of designated EPC states. In these tables we present data on the 
distribution of the exogenous variables as well as data on the bivariate relationship between these 
variables and the incidence of opposition. We present these statistics for the total number of patents 
in the sample, and separately for the dominating national groups of patent owners. The most 
important non-European owner nations are the U.S., accounting for approximately 34 percent, and 
Japan accounting for roughly 19 percent of the total number of patents, respectively. 
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As is evident from Table 2, forward citations are highly correlated with the likelihood of 
opposition in the overall sample and in each of the national groups. The rate of opposition 
increases monotonically with the number of forward citations. The group of patents receiving more 
than 9 forward citations is in fact attacked in 44.6 percent of all cases, nearly twice as often as the 
group of patents which is referenced 7 to 9 times. It is also clear from Table 2 that Japanese patents 
are attacked far less frequently than those of U.S. and other owners, but it is not clear whether this 
is driven by differences in patent quality (in the sense that Japanese patents are legally "stronger"), 
or by differences in patent value (in the sense that Japanese patents tend to be more incremental 
than patents from other owner nations). 
Table 3 reveals that there is also a significant relationships between backward citations and the 
incidence of opposition, although the relationship appears to be weaker than in the case of forward 
references. This result also holds for the sub-samples of Japanese owned patents and those mainly 
held by European owners. However, backward citations are not significantly correlated with the 
likelihood of opposition when restricting the sample to U.S. owners. 
Table 4 summarizes the relationship between opposition and the number of references to the non-
patent literature. Again, in the overall sample we find a significant relationship (p=0.029), but this 
correlation is mainly driven by the U.S. sub-sample. References to the non-patent literature are not 
significantly associated with the likelihood of opposition for Japanese owned patents and for 
patents owned by mostly European patent holders. These two results are somehow plausible 
considering the practical aspects of filing in the two countries. In the U.S. the “best-mode” 
requirement not only obliges the applicant to disclose the optimal method of carrying out his 
invention, but he is also forced to protect himself against any possible objections of state of the art 
in possible legal disputes by quoting any kind of literature that could be related to the patentability 
of his invention. Thus, whereas citations of European applicants and examiners refer to the 
important relevant literature, U.S. owner may by habit reveal additional information that is 
correlated with the incidence of opposition. 
Finally, the results summarized in Table 5 confirm that the likelihood of opposition is correlated 
positively with the number of designated states in our bivariate analysis. However, the relationship 
does not appear to be a monotonic one. The relationship is also insignificant in the Japanese patent 
sub-sample, suggesting again that there may be some heterogeneity across owner nations. 
Obviously, the decision to seek patent protection in a particular country may also be driven by 
variables that we have considered before, e.g., the patent's anticipated legal strength. It will 
therefore be important to study the effects of all variables described before in a multivariate 
analysis. 
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5.2 Multivariate Specification and Results 
We now discuss the results from our multivariate probit specifications which are summarized in 
Table 6 and Figure 4. We report both the probit coefficients (columns 1a and 2a) and the marginal 
effects (columns 1b and 2b) which are computed for the sample means. Columns 1a and 1b refer to 
the full sample of 13,389 patents. In columns 2a and 2b, we restrict the sample to patent holders 
which had received at least 10 patent grants by 1998. This probit regression therefore excludes 
firms and individuals which do not participate on a regular basis in the patenting process. We will 
focus in our discussion on columns 1a and 1b and then consider the differences between the results 
in column 1a and 1b, and columns 2a and 2b, respectively. 
First, family size displays the expected effect on the likelihood of opposition. Per logarithmic unit, 
the likelihood of opposition increases by 3.3 percent (S.E. 0.70). The effect is precisely estimated 
and indicates a strong relationship. Using a dummy variable approach as a nonparametric 
alternative specification, we confirm these estimates. The following figures come from separate 
estimates not reported in Table 6. Taking patents with fewer than 5 designated states as the 
reference group, the likelihood of opposition increases by 5.23 (S.E. 1.40) percentage points if the 
number of designated states is between 5 and 11. It increases by 6.0 (S.E. 1.1) percentage points 
(relative to the reference group) for the group of patents with 11 to 14 designated states and by 9.3 
(3.3) percentage points for patents with more than 15 designated states. 
The strongest predictor of opposition are forward references to a patent. In order to model the 
impact of this variable in a flexible way, we have included dummy variables for the number of 
forward references. The joint test of these variables in Table 6 reveals that they are highly 
significant. The size of the coefficients and the standard errors are plotted in Figure 4. Increasing 
the number of citations from zero to one raises the likelihood of opposition by 2.5 (S.E. 0.7) 
percentage points; increasing the number from zero to ten citations yields an increment in the rate 
of opposition of 20.2 (S.E. 9.8) percentage points. In general, these multivariate results are 
consistent with the descriptive statistics in Table 2. They confirm our view that more valuable 
patents face a much higher likelihood of opposition. Thus, the result is also consistent with the 
positive effect of family size. 
As in the study of U.S. patent litigation by Lanjouw and Schankerman (2001), we find that the 
effect of the scope variable (number of different four-digit SIC codes) is negative and quite small.  
Moreover, the effect is barely significant in column 2b, and not significant in column 1b. This 
result is apparently in contrast with Lerner's study who reports a positive correlation between scope 
and the market value of the biotechnology firms owning the respective patents. A previous study 
by Harhoff, Scherer and Vopel (1999) did not find any significant relationship between this 
variable and the value of individual patents. Indirectly, we confirm this result here using a sample 
that is much closer to Lerner's biotechnology data than the previously used ones. We conclude that 
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the scope variable may not carry much explanatory weight once other proxies for the patent’s value 
are included in a regression. 
We have argued that interactions between patent holders in "crowded" fields with a large 
cumulative number of patents should lead to an increase in the rate of opposition, since competitors 
are more likely to pursue similar research paths. At the same time, opposition by competitors is 
likely to be a function of the patent holder's portfolio. We model these effects by including a 
measure for “crowdedness”, a measure for the size of the patent portfolio of the firm holding the 
opposed patent, and the interaction term. The results for these variables are not easy to interpret. 
“Crowdedness” has the anticipated positive marginal effect on opposition, but it is quite small and 
only works through the interaction term. For firms with the average number of patents (26,8 
patents), an increase in the number of patents in the field by 1000 patents raises the likelihood of 
opposition by 0,14 percentage points. For firms with strong patent portfolios (e.g. 300 patents), the 
effect is on the order of 0.4 percentage points. Since the differences between our IPC groups are 
quite large in terms of “crowdedness”, we can explain a difference on the order of about 1 
percentage point in the likelihood of opposition. The effect of the firm's own portfolio is much 
larger. Adding 100 patents to the average portfolio of 26.8 patents reduces the rate of opposition by 
2.7 percentage points. Again, the effect is highly significant. This effect is reduced in crowded 
areas – for most “crowded” fields it is on the order of 1 percentage point. These results parallel the 
evidence in Lanjouw and Schankerman (2001) who find in their study of U.S. patent litigation 
cases that litigation is more likely to occur whenever patents appear to form the basis of a sequence 
of technologically linked inventions. 
The number of backward references has no significant impact on the likelihood of opposition. 
However, the composition of the backward references does matter considerably. We noted before, 
that X documents among the cited patents pose a particularly strong threat to patent validity, while 
A documents merely summarize the state of the art. Consistent with this view, we find that 
increasing the share of X documents from, e.g., zero percent to fifty percent would lead to a direct 
increase in the opposition rate of about 1.2 percent. Moreover, since the share of A documents may 
be reduced, there is an additional effect of similar order. Our results demonstrate that the WIPO 
classification of cited documents in the research report could become an interesting variable for 
empirical researchers interested in modelling litigation or the value of patent rights. To the best of 
our knowledge, this information has not been used before. 
Somewhat surprisingly, we cannot find any significant correlation between the likelihood of 
opposition and the number of references to the non-patent literature. In Harhoff, Scherer and Vopel 
(1999), there is clear evidence for German patents that a strong correlation exists between these 
references and patent value. A possible explanation of our results in Table 6 would be that the 
increase in value documented by a large number of non-patent literature references is accompanied 
by an increase in the legal “robustness” of the patent right. While increased value may help to 
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make opposition look attractive to competitors, the links to scientific results may reduce the 
chances of a successful outcome of the challenge. We will investigate this explanation in future 
work. 
We hypothesized that patents in fields with higher economic, legal or technical uncertainty and 
subsequently higher asymmetry of information should attract opposition more frequently. These 
expectations are confirmed in our estimates. The joint test for significance of those variables 
characterizing the IPC classification of the patent yield a strong result – clearly, there are important 
differences across these groups. Taking the group C12M (apparatus for enzymology or 
microbiology) as our reference case, we would expect all other IPC groups included in our study 
(see Table 2 for a description) to display higher opposition rates. After all, the C12M classification 
refers to patented machinery which may be much closer in terms of the patented inventions to 
mechanical engineering fields than to recombinant DNA biotechnology. Our estimates show that 
the strongest increment in opposition rate occurs in the IPC fields C12N (microorganisms or 
enzymes – 9.2 percentage points, S.E. 2.9) and C12P (fermentation or enzyme-using processes – 
7.6 percentage points, S.E.3.1). Classical pharmaceuticals (A61K, without cosmetics) face an 
opposition rate that is only 6.0 percentage points (S.E. 2.0) higher than in the reference group. The 
other IPC classes have an even lower coefficient. 
Finally, we do not find robust evidence that patents held by individual inventors are more or less 
likely to be challenged. Moreover, the coefficients for the nationality of the owner do not display a 
clear pattern. Taking German applicants as the reference group, applicants from the U.S., 
Switzerland and a residual group of smaller countries do not face incrementally different 
opposition rates. Japanese owners have a significantly lower rate of opposition (by 3.8 percentage 
points, S.E. 0.9), and UK owners face higher opposition rates (by 2.5 percentage points, S.E. 1.1). 
However, these variations may very well reflect differences in technical sub-fields which we have 
not controlled for sufficiently. 
6 Conclusions and Further Research 
This paper has presented an empirical analysis of the opposition procedure at the European Patent 
Office. To the best of our knowledge, this is the first econometric study of its kind. The previous 
lack of interest cannot be attributed to the fact that the topic is unimportant – the EPO grants about 
40,000 patent rights per year, and roughly 8 percent of these are opposed. Hence, opposition may 
not only affect the incentives for patenting and R&D, it may also serve a valuable function in 
weeding out weak patents and resolving legal uncertainty with regard to particularly valuable 
inventions. Given our results, the latter interpretation appears to be the most relevant one. We find 
that correlates of patent value such as received citations and the number of countries for which the 
EPO patent is designated are relevant predictors of the likelihood of opposition. Moreover, 
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uncertainty and asymmetric information appear to play a role as suggested by theoretical models of 
case selection for trial: in certain new technical areas as delineated by the IPC classification, the 
likelihood of opposition is considerably larger than in more mundane areas. Patents which are 
presumably characterized by intensive discussions between examiners and applicants also face a 
much higher risk of opposition – we attribute this to the pronounced informational asymmetries 
facing the opponent of one of these patents. 
Naturally, this study is merely a first glimpse at an important institution, and more structured 
attempts, both for particular technical fields and the population of patents, should follow. The 
expected probability of successful opposition plays an important role in such models, hence that 
analysis will have to await the arrival of reliable outcome data. Moreover, it will be important to 
study the duration of the opposition process – if the process is used strategically by some 
opponents to create legal uncertainty about the status of a patent right, we should be able to detect 
a pattern in which these cases take longer to be resolved, even after accounting for observable 
differences in the potential value of the patent rights. The question of who opposes whom is of 
similar interest – again, a pattern of frequent attacks of small or young firms by established players 
would be a worrisome result. If cases are indeed selected strategically, we may be able to find an 
analogue of Lerner’s (1998) observation who finds that “patenting in the shadow of infringement” 
leads start-up firms in the biotechnology sector to patent in niches in which a legal conflict with 
large players is unlikely to occur. Again, this result would not be encouraging, since it points to a 
strategic mechanism by which large players can affect the direction of research chosen by new 
entrants. Currently, however, there is no evidence to that avail.  
Finally, we should also emphasize that the opposition procedure is not only used by competitors of 
patent applicants. In particular in the field of biotechnology, a large number of public interest 
groups is trying to influence European patenting practice by filing opposition cases against certain 
patents. It should be interesting to study the political economy of this process as well as the 
detailed structure of the institution in further work. 
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Figure 1 














































Note:  Opposition frequency is computed as the number of patent grants opposed divided 
by the number of all patents granted in a given year. The first EPO patent grants 
were issued in 1980. 
Source:  European Patent Office Annual Report 1999, Table 7.6 










1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5

























Forward Citations and the Likelihood of Opposition 





















  29 
Table 1 
Descriptive Statistics for the Biotechnology  





Mean S.D. Min. Max. 
opposition cas 0.0864  0 1 
forward citations (received within 4 yrs after 
filing of application) 
0.914 1.800 0 36 
references to the non-patent literature 1.749 1.995 0 29 
backward citations (references to the patent 
literature) 
2.159 2.203 0 19 
share of X documents among backward 
citations 
0.086 0.229 0 1 
share of A documents among backward 
citations 
0.196 0.338 0 1 
number of designated states 
 
10.445 3.437 1 17 
cumulative number of patents within four-
digit ipc/1000 
2.486 2.144 0.001 7.394 
cumulative number of patents by patent 
holder/1000 
0.027 0.043 0.001 0.322 
scope (number of 4-digit IPC classifications) 1.934 1.936 1 23 
IPC A61K – preparation for medical, dental, 
or toilet purposes 
0.552  0 1 
IPC C07G – compounds of unknown 
constitution 
0.009  0 1 
IPC C12M – apparatus for enzymology or 
microbiology 
0.030  0 1 
IPC C12N – microorganisms or enzymes; 
composites thereof 
0.215  0 1 
IPC C12P – fermentation or enzyme-using 
processes 
0.110  0 1 
IPC C12Q – measuring or testing processes 
involving enzymes 
0.083  0 1 
individual owner 0.065  0 1 
owner from U.S. 0.338  0 1 
owner from U.K. 0.074  0 1 
owner from France 0.067  0 1 
owner from Japan 0.191  0 1 
owner from Switzerland 0.025  0 1 
owner from other country 0.115  0 1 
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Table 2 
Forward Citations and Incidence of Opposition 
Incidence of 
Opposition – All 
Patents 
Incidence of Opposition – 
Patents of U.S. Owners 
Incidence of Opposition - 
Patents of JP Owners 
Incidence of Opposition 
- Patents of Other 
Owners 




% of Total 
Observations 
Mean Obs. Mean Obs. Mean Obs. Mean 
0 8,178 61.08 0.066 2,840 0.077 1,312 0.022 4,026 0.073 
1-3 4,319 32.26 0.101 1,303 0.111 1,062 0.060 1,954 0.116 
4-6 651 4.86 0.160 245 0.159 146 0.096 260 0.196 
7-9 158 1.18 0.234 77 0.195 31 0.161 50 0.340 
>9 83 0.62 0.446 54 0.481 5 0.200 24 0.417 
Total 13,389 100 0.087 4,519 0.098 2,556 0.044 6,314 0.095 
          
c2    275.30  123.98  43.81  126.01 
(p-value)   (0.000)  (0.000)  (0.000)  (0.000) 
 
Note: The c2 statistics (and p-values) refer to a Pearson test of the hypothesis that there is no relationship between the number forward citations and the incidence of opposition within the 
indicated group of patents. 
Table 3 
Backward Citations and Incidence of Opposition 
Incidence of Opposition – 
All Patents 
Incidence of Opposition 
– Patents of U.S. 
Owners 
Incidence of 
Opposition - Patents of 
JP Owners 
Incidence of 
Opposition – Patents 




Number of Observations % of Total 
Observations 
Mean Obs. Mean Obs. Mean Obs. Mean 
0 4,056 30.29 0.085 1,428 0,096 492 0,045 2,136 0,087 
1-3 6,134 45.81 0.080 2,050 0.100 1,448 0.039 2,636 0.085 
4-6 2,628 19.63 0.095 836 0.096 519 0.044 1,273 0.116 
7-9 467 3.49 0.122 167 0.090 81 0.086 219 0.160 
>9 104 0.777 0.173 38 0.158 16 0.250 50 0.160 
Total 13,389 100 0.087 4,519 0.098 2,556 0.044 6,314 0.095 
          
c2    23.67  1.87  20.26  23.96 
(p-value)   (0.000)  (0.759)  (0.000)  (0.000) 
 
Note:  The c2 statistic (and p-value) refer to a Pearson test of the hypothesis that there is no relationship between the number of backward citations and the incidence of opposition within 
the indicated group of patents.  
  31 
Table 4 
References to the Non-Patent Literature and Incidence of Opposition 
Incidence of 
Opposition – All 
Patents 
Incidence of Opposition – 
Patents of U.S. Owners 
Incidence of Opposition - 
Patents of JP Owners 
Incidence of 
Opposition - Patents of 
Other Owners 
Number of 





% of Total 
Observations 
Mean Obs. Mean Obs. Mean Obs. Mean 
0 3,618 27.02 0.099 1,132 0.082 656 0.052 1,830 0.101 
1-3 7,719 57.65 0.084 2,670 0.096 1,417 0.046 3,632 0.091 
4-6 1,630 12.17 0.086 558 0.116 404 0.032 668 0.093 
7-9 318 2.38 0.132 113 0.221 67 0.015 138 0.116 
>9 104 0.78 0.125 46 0.130 12 0.000 46 0.152 
Total 13,389 100 0.087 4,519 0.098 2,556 0.044 6,314 0.095 
          
c2   10.78  25.35  4.29  4.00 
(p-value)   (0.029)  (0.000)  (0.368)  (0.406) 
 
Note:  The c2 statistic (and p-value) refer to a Pearson test of the hypothesis that there is no relationship between the number of 
references to the non-patent literature and the incidence of opposition within the indicated group of patents. 
Table 5 
European Familiy Size and Incidence of Opposition 
Incidence of 
Opposition – All 
Patents 
Incidence of Opposition – 
Patents of U.S. Owners 
Incidence of Opposition - 
Patents of JP Owners 
Incidence of Opposition 







% of Total 
Observations 
Mean Obs. Mean Obs. Mean Obs. Mean 
1-4 1,154 8.62 0.030 277 0.039 659 0.023 1,154 0.041 
5-10 4,109 30.69 0.083 1,165 0.104 1,115 0.056 4,109 0.085 
11-14 7,334 54.78 0.100 2,832 0.104 715 0.048 7,334 0.101 
>14 792 5.92 0.062 245 0.065 67 0.015 792 0.067 
Total 13,389 100 0.087 4,519 0.098 2,556 0.044 6,314 0.095 
          
c2   1779  15.498  12.710  19.539 
(p-value)   (0.000)  (0.001)  (0.005)  (0.000) 
 
Note:  The c2 statistic (and p-value) refer to a Pearson test of the hypothesis that there is no relationship between the number of 
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dummy Variables for four-digit IPC 





dummy variables for application years 





dummy variables for ownership 





log L 3705.97 -2413.89 
c2 (df) 469.86 (53) 384.14 (53) 
pseudo-R-squared 0.0596 0.0737 
N 13,389 8,644 
 
Notes: Dependent Variable: Patent Opposition (0/1). Column 1a and 2a contain coefficient estimates (standard errors) unless a 
chi-squared statistic is given. Columns 1b and 2b show marginal effects (standard errors). All probit equations contain 
dummy variables for the application year and for the nation of the owner. See the text for explanations. 
